Plasmacure is a Nijmegen-based MedTech company whose flagship product, PLASOMA, applies cold plasma directly to complex wounds to accelerate healing. The PLASOMA pulser delivers controlled electric pulses to a disposable pad, generating cold plasma at the wound that acts as a potent antimicrobial and stimulates blood flow and cell regeneration. The company reports a randomized controlled trial in which PLASOMA closed up to 2.5 times more complex wounds than standard care. Plasmacure plans to scale globally and advance adoption of PLASOMA for indications including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. To support expansion, the company announced a €6 million Series A and secured additional financing for U.S. regulatory and reimbursement pathways. Management frames the financing as enabling a U.S. rollout and broader global commercialization.

Total raised

$17M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2025